PROCEPT BioRobotics Third Quarter 2022 Results: Revenues Exceed Expectations, EPS In Line


PROCEPT BioRobotics (NASDAQ:PRCT) Third Quarter 2022 Results

Main financial results

  • Revenue: $20.3 million (up 135% compared to Q3 2021).
  • Net loss: $22.6 million (expanded loss of 60% from Q3 2021).
  • Loss of $0.51 per share.
NasdaqGM: PRCT Earnings and Revenue Growth November 6, 2022

All figures shown in the table above are for the 12 month period (TTM)

PROCEPT BioRobotics Revenue Outlook

Going forward, revenue is expected to grow 39% per year on average over the next 3 years, compared to a growth forecast of 7.5% for the US medical device industry.

Performance of the American medical equipment industry.

Shares of the company are down 12% from a week ago.

Risk analysis

You should find out about the 2 warning signs we spotted with PROCEPT BioRobotics.

Valuation is complex, but we help make it simple.

Find out if PROCEPT BioRobotics is potentially overvalued or undervalued by viewing our full analysis, which includes fair value estimates, risks and warnings, dividends, insider trading and financial health.

See the free analysis

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts only using unbiased methodology and our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to bring you targeted long-term analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative materials. Simply Wall St has no position in the stocks mentioned.


Comments are closed.